Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share news regarding a groundbreaking development in cancer treatment. The company's lead drug formulation, Rutherrin®, has shown preclinical success in being activated by Metformin, a widely used diabetes medication, without the need for light or radiation. DuMoulin-White explained that both Rutherrin® and Metformin have been scientifically proven to cross critical biological barriers, including the blood-brain barrier and tumor-specific blood barriers.
This discovery opens the possibility of precisely targeting cancer cells throughout the body, including within the brain, with Rutherrin®, which can then be synergistically activated by Metformin. Metformin, an anti-diabetic drug approved by the U.S. Food and Drug Administration (FDA) in 1994 for the treatment of Type 2 diabetes, is the only anti-diabetic medication currently recommended by the American Diabetes Association for the prophylactic treatment of prediabetes.
This new application of Metformin in cancer treatment, in combination with Rutherrin®, represents a significant advancement in the potential to target and destroy cancer cells with unprecedented precision. This latest research now supports a whole new line of research looking to specifically, identifying additional drugs, as potential synergistic candidates for activating Rutherrin in the destruction of various cancers.